Introduction
Ginsomin is an over-the-counter nutritional supplementwhich possesses the natural energy-boosting properties of Panax ginseng and essential traditional vitamins and minerals.Panax ginseng has been used as a multipurpose medicine for centuries, especially in Asian countries (Yun, 2001; Park et al., 2005) . Its root extract contains ginseng saponins referred to as ginsenosides,which play a major role in most of the physiological and pharmacological activities of ginseng (Yue et al., 2007; Park et al., 2012) . Korean panax ginseng has been used as a general herbal tonic and is also knownto have adaptogenic properties (Kim and Park, 2010) . Ithas been reported to beuseful in the treatment of various human diseases (e. g. rheumatoid arthritis, sexual dysfunction, ischemic injury and diabetes mellitus) Shin et al., 2011) , it promotes longevity, and assists the body in stress management (Lee et al., 2008) and homeostatic balance (Choi, 2008) . It also has antioxidant properties due to its ability to scavenge free-radicals and to neutralize free ions induced by lipid peroxidation (Karadeniz et al., 2009 ). Other than the energising properties of ginseng, Ginsomin ® is also fortified with vitamins and minerals believed to help improve physical and mental performance day and night.These vitamins and minerals include B complex vitamins and protective anti-oxidants like Vitamin C and E, natural Beta-Carotene, Copper, Selenium and Zinc. Ginsomin is believed to help in increasing subjective energy levels and to protect the body against stress and fatigue. Acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) is a para-aminophenol derivative commonly used as analgesic and antipyretic (Garry and Kieran, 2005) . It is generally considered safe when the recommended dose is taken but may cause severe hepatic damage when an overdose is administered both in humans and experimental animals (Sener et al., 2005) due to excessive production and/or decreased glutathione conjugation of N-acetyl-parabenzoquinone imines (NAPQI) which damages cell membranes (Kwan et al., 1995) .More recent concerns are suspicions that repeated ingestion, even at clinically-prescribed doses may be associated with hepatic injury (Jalan et al., 2006) .Acetaminophen toxicity has been attributed either to an acute overdose, repeated excessive dosing or use of a variety of medications containing acetaminophen (Gum and Cho, 2013b) . Toxiceffects are largely not from the drug itself but due to the formation of highly electrophilic and reactive intermediate metabolite, N-acetyl-para-benzoquinone imine (NAPQI), which at therapeutic doses preferentially conjugates with hepatic glutathione sulfidryle (GSH) (Gum and Cho, 2013b) . However in overdose, large amounts of acetaminophen are metabolised by oxidation because of saturation of the glucuronide and sulphate conjugation pathway (Benjamin et al. 2002; Pajoumand et al., 2003) , and the protective intracellular glutathione (GSH) stores are therefore depleted faster than they can be regenerated due to excessive production of NAPQI. NAPQI formed covalently binds to essential nucleophilic macromolecules such as cellular proteins and membrane macromolecules in the hepatocyte therefore initiating lipid peroxidation leading to cell death or injury and release of intracellular contents including a significant release of liver enzymes especially the transaminases in plasma (Yen et al., 2008) . This may lead to hepatic necrosis, renal tubular necrosis, hypoglycaemic coma and death as a result of its toxicity (Gum and Cho, 2013a) .
In many parts of the world, acetaminophen is cheap and easily gotten without a need for prescription. There exists a subset of the population (usually blue collar employees) who ingest acetaminophen daily, (to help in coping daily with physically-demanding work) many times without adhering to clinically prescribed doses. This group of people are at risk of acetaminophen toxicity.
It is common practice in many developing countries for people to rely on herbal or other natural products in the management of illnesses, including toxicities.A number of studies monitoring beneficial effects of natural or herbal products against paracetamol-induced toxicities have been carried out, with results that point towards hepatoprotection (Lee et al., 2001; Chattopadhyay, 2003; Onaolapo and Onaolapo, 2012; Fakurazi et al., 2012; Osama,2013) .One of the main limitations to use of herbs (especiallyin third world countries where they are popular) is the lack of standardized formulationsas well as the absence of detailed dosing regimens. The result is indiscriminate use and a tendency to develop hepatic and/or renal injury from herbal product overdose. The question here is, can there be a standardized herbal product that is useful in prevention of acetaminophen hepatotoxicity?
Herb-containing supplements like Ginsomin which until now has been marketed and sold mainly for its immune and mental-health boosting properties is believed to increase the body's resistance to stress and fatigue. Ginsomin supplementation may offer protection against liver injury considering that the potential beneficial effects of Korean panax ginseng (which is the main constituent of ginsomin) in the management of several medical conditions is the subject of several studies (Kitt et al., 2000; Zhang et al., 2008; Lu et al., 2009; Ramesh et al., 2012; Osama, 2013; Mohammed et al., 2015) . Since Ginsomin is standardized and its dosing formula well-documented, incidences of overdose or indiscriminate use is much less.Also it is fortified with a lot of essential vitamins and minerals all of which may increase its antioxidant and immune modulatory property.
Materials and Methods
Ginsomin capsules (Mega LifeSciencePty.Ltd.,Australia),Acetaminophen(paracetamol) tablets (Juhel Pharmaceuticals, Lagos, Nigeria). All the diagnostic kits for assaying hepatic function tests were obtained from RandotLaboratories. All other chemicals were of analytical grade. Ginsomin capsule containing 50 mg of ginseng extract and acetaminophen tablets (500 mg) were dissolved separately in measured volumes of normal saline and administered orally via a cannula.
Animal care and management
Forty (40) adultSwiss mice (Empire Breeders, Osogbo, Osun State, Nigeria) weighing between 20-22 g were used. Mice were housed in plastic cages measuring 16 x 12 x 10 inches (8 mice in each cage). Housing was a temperaturecontrolled (22.5°C ±2.5°C) quarters with 12 hours of light at the animal house of the College of Health Sciences, Ladoke Akintola University of Technology, Osogbo, Osun State, Nigeria. Mice had free access to food and water. The experimental protocol was approved by the Ladoke Akintola University of Technology Animal Ethics Committee. All rules applying to animal safety and care were observed.
Experimental method
Animals were assigned randomly to five (5) groupsof eight (8) mice each. Theyreceived vehicle (normal saline) or pre-treatment with one of three doses of ginsomin (0.5, 1.0 and 1.5 mg/kg body weight respectively) for 14 days before administration of acetaminophen (800 mg/kg) daily for 3 days. There was a negative control group that received acetaminophen without drug pre-treatment.Animals were weighed weekly using a Mettler weighing balance (Mettler Toledo Type BD6000, Greifensee, Switzerland). At the end of the experimental period, animals wereanaesthetised with diethyl-ether, sacrificed by cervical dislocationand samples taken via an intracardiac puncture for estimation of alanine and aspartate transaminase (ALT, AST),total protein and plasma albumin levels. Sections of the right lobe of the liverwerecut, processed for paraffin-embedding and stained with hematoxylin and eosin forgeneral histological study.
Biochemical analysis
Blood samples were collected into lithium-heparin bottles. Plasma samples were then separated and stored at -20ᴼC for biochemical analysis. For the assessment of the liver functions of the mice, plasma total protein was measured using direct Biuret method (Kingsley andFrankel, 1939 ) plasma albumin was estimated by using Bromocresol green method (Dormas et al., 1971) and also the activities of liver enzymes Aspartate and Alanine transaminase (AST, ALT) in plasma were determined using colorimetric methodby measuring concentration of oxaloacetate hydrazone and the pyruvate hydrazones formed with 2,4-dinitrophenyl-hydrazine, respectively. The colour was measured at 546 nm according to Reitman and Frankel (1957) .
Liver Histology
Liver was dissected out, washed in normal-saline and sections of the right lobe sectioned and fixed in 10% formolsaline and processed for paraffin-embedding.Sections were taken at 5 microns, dehydrated in alcohol, cleared in xylene and stained with haematoxylin and eosin for general histological study. An Olympus BX50 digital light microscope was used to examine the slides and acquire photomicrographs.
Statistical analysis
All data were first tested for normality and variance homogeneity, prior to statistical analysis. Having been found to be normally distributed, and variances homogeneous, data was then analysed by one way analysis of variance (ANOVA) test to determine effects of the treatments using Chris Rorden's ezANOVA statistical package, (version 0.98). Post-hoc tests with Tukey's multiple comparison test (Tukey HSD) were used to determine the source of a significant effect. Results were expressed as Mean ± S.E.M. and p < 0.05 taken as accepted level of significant difference from control. Figure 1 represents the effect of ginsomin on body weight over a 14 day period. Body weight was measured as percentage change in weight defined as the difference between the final and initial body weights divided by initial weight multiplied by 100. There was a significant (F=161, p<0.001) decrease in weight gain at all doses of ginsomin compared to vehicle, and an increase in percentage weight gain compared to acetaminophen control. Figure 2 shows the effects of ginsomin on aspartate transaminase levels. There was a significant (F= 61.5, p<0.001) increase in serum aspartate transaminase levels at all doses of ginsomin compared to vehicle and a decrease compared to acetaminophen control. Figure 3 shows the effects of ginsomin on alanine transaminase levels. There was a significant (F= 34.1, p<0.001) increase in serum alanine transaminase levels at 0.5 mg/kg of ginsomin compared to vehicle and a decrease at all doses of ginsomin compared to acetaminophen control.At 1.0 mg/kg of ginsomin, the increase seen compared to vehicle was only visual while at 1.5 mg/kg there was a visual decrease. Figure 4 represents the effects of ginsomin on total protein. There was a significant (F= 127, p<0.001) increase in total protein at all doses of ginsomin compared to vehicle, and a decrease at 0.5 and 1.0 mg/kg of ginsomin compared to acetaminophen control, at 1.5 mg/kg of ginsomin, the difference seen compared to acetaminophen control was only visual. Figure 5 represents the effects of ginsomin on serum albumin. There was a significant (F=24.6, p<0.001) increase in serum albumin at all doses of ginsomin compared to vehicle and no significant difference compared to acetaminophen control. 
Results

Effect of oral ginsomin on body weight
Effect of ginsomin on aspartate transaminase
Effect of ginsomin on alanine transaminase
Effect of ginsomin on total protein
Effect of ginsomin on serum albumin
Effect of ginsomin on liver morphology
Examination of haematoxylin and eosin stained liver sections of animals that were administered vehicle (figure 6a) revealed sheets of radially-arranged hepatocytes around a terminal hepatic venule. There were small intervening sinusoidal spaces between cords of hepatocytes and hepatocytes had well-staining nuclei; these features are in keeping with normal histology. Liver slides from mice in the acetaminophen l group (figure 6b) showed poorly-staining hepatocytes with loss of normal architecture, numerous vacuoles, dilatation of the central vein and numerous pale-staining irregularly-shaped hepatic nuclei;these features are in keeping with hepatic injury. Examination of the slides from animals in group that received ginsomin at 0.5 mg/kg (figure 6c), 1.0 mg/kg (figure 6d) and 1.5 mg/kg (figure 6e) showed varying degrees of protection from liver injury as evidenced by mild loss of normal liver architecture with some radially-arranged cords of hepatocytes with normal nuclei, a few hepatocytes with either pale or deeply staining nuclei. There was also dose-related reduction in central vein dilatation;these features are in keeping with probable protection from acetaminophen overdose. 
Discussion
Acetaminophen is acommon, over-the-counter medication known to be hepatotoxic at doses above the therapeutic dose, as a result of excessive production of highly electrophilic intermediate metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which binds covalently to nucleophilic macromolecules such as cellular proteins and lipids in the hepatocytes, inducing lipid peroxidation (Muriel et al., 1992) .This studyset out to ascertain the possible hepatoprotective capability of oral ginsomin in acetaminophen overdose in mice.
The results of this study showed that acetaminophen,at doses administered caused significant reduction in weight, an increase in the AST, ALT, total protein and decrease in plasma albumin levels associated with histological evidence of hepatotoxicity (disorganisation of the hepatic architecture with numerous vacuoles within the hepatocytes, dilated central vein and irregularly shaped nuclei). Pre-treatment with ginsomin however resulted in dose-related protection of the liver from the effects of acetaminophen-over dose.
In a number of toxicological studies,parameters such as body weight and relative organ weights are important criteria for evaluation of toxicity (Crissman et al., 2004) . In this study, a reduction in body weight seen with acetaminophen overdose corroborates findings from an earlier study in rats (Onaolapo and Onaolapo, 2012) in which similar results were seen.Weight loss from acetaminophen overdose may be attributed to a reduction in food intake or poor food palatability. Acetaminophen overdose may also cause generation of free radicals from increase in oxidative stress and alterations in antioxidant levels which may put a burden on metabolism and cause weight loss. Pre-treatment with ginsomin which is known to have high antioxidant activity is seen to attenuate the effects of acetaminophen overdose on body weight.
Liver enzymes (AST and ALT)are cytoplasmic in origin and are found in the blood in significant quantities only after hepatic injury; however,ALTis considered the more reliable marker of hepatic injury of the two [24] . In this study, the decrease in the level of ALT and AST (compared to ACP group)may be attributable to the protective effect of ginsomin. A number of studies have shown ginseng, a major component of ginsomin is hepatoprotective and this function can be attributed to its antioxidant activitythat arises from constituents such as ginsenosides, phenolic acids and flavonoids (Karakus et al., 2011; Ramesh et al., 2012; Mohamed et al. 2015) .
The liver plays a major role in metabolism and has a number of other functions in the body including plasma protein synthesis. With acetaminophen overdose, there is hepatic injury and a consequent decrease in plasma albumin; the liver cells may compensate for the decrease in albumin production by increasing the production of globulins and therefore increasing total protein.This study showed a significant decrease in plasma albumin and an increase in total protein at all doses of ginsomin compared to vehicle.Also, a significant decrease in total protein at doses of 0.5 and 1.0 mg/kg of ginsomin was seen compared to acetaminophen control. This result shows the ameliorative effect of ginsomin on total protein by decreasing its level in ginsomin pre-treatment groups.Liver histology showed that acetaminophen overdose was associated with hepatic injury in mice in the acetaminophen without pre-treatment group, compared to the vehicle. However, pre-treatment with ginsomin resulted in significant qualitative improvement in liver architecture compared to acetaminophen without pre-treatment, with the greatest improvement seen at 1.5 mg/kg.
In conclusion, this study demonstrated that ginsomin administration was protective against the ill effects of acetaminophen overdose on liver cells, suggesting that ginsomin capsules may be useful in protecting against development of liver injury in acetaminophen overdose.
